Dr. Janar Jenis, Professor of Faculty of Chemistry and Chemical Technology, Al-Farabi Kazakh National University (KazNU), and obtained her MSc and PhD (2010-2012) in organo-metalic chemistry, catalyze and plant chemistry, at KazNU, Almaty, Republic of Kazakhstan. 2010-2012, Post-doctoral researcher at Faculty of Pharmaceutical Sciences, Hoshi University, Tokyo, Japan. 2014-2016 Visiting researcher: Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences (CAS), Urumqi, China. And 2016-2018 Senior researcher at Division of Applied Life Science (BK21 plus), IALS, Gyeongsang National University, Jinju, Republic of Korea. Scientific area is related on isolation, as well as the biological assessment and modification of natural compounds derived from medicinal plants used in Kazakh Medicine and study of the structural analysis of bioactive natural products, using modern 2D NMR and MS spectroscopic techniques. She is a membership of Asian Society of Natural Products (ASNP) and Malaysian Natural Products Society (MNPS).
Traditionally natural products have played an important role in developing of natural product chemistry which continues to expand to exciting new frontiers of great importance in medicine. In Kazakh Medicine,the plant resources had efficiently using in the treatments of different kinds of diseases such as bronchitis, bronchial asthma, hepatitis, urethritis, chronic rheumatoid arthritis, nephritis, urolithiasis, pharyngitis, periodontitis, stomach pain, hyperacidity, diarrhea, hemostasia, metrorrhagia, snakebite, cancer and so on. In Kazakhstan grow over six thousand kinds of plants in which more than 6000 species of highest vascular plants, about 5000 species of mushrooms, 4851 species of lichen, more than 2000 species of seaweed are registered.
Nowadays, production of medicines in the Republic of Kazakhstan is 11% (including vaccines - 1.1%), veterinary drugs 78% (mainly manufacture of drugs from imported substances), while other products are imported into the country. The main problem is the lack of original domestic biotechnological drugs in the presence of promising experimental development. To date, the production of genetically engineered drugs virtually not regulated, while there are original domestic or joint developments that passed or are in the process of passing of pre-clinical and clinical studies. Kazakhstan's medical potential, including the investment attractiveness, gives us the ability to effectively absorb the advanced experience of China's health system development, what makes the necessary conditions for the movement of relations between our countries to a higher level of cooperation.